On September 26, 2024, the Board of Directors of the Company (the “Board”) appointed Lauren Riker, the Company’s current Senior Vice President of Finance and principal accounting officer, to also serve as interim Chief Financial Officer of the Company (including as principal financial officer and continuing as principal accounting officer for Securities and Exchange Commission reporting purposes), effective October 1, 2024.
Appointed
(interim)
Ryan Fischesser
Interim Principal Financial Officer and Interim Principal Accounting Officer
On September 23, 2024, Caribou Biosciences, Inc. (the “Company”) designated Ryan Fischesser, the Company’s current Vice President of Finance and Controller, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of 5:00 p.m. Pacific time on September 27, 2024.
Mr. O’Byrne serves as the Company’s principal financial officer and principal accounting officer through September 27, 2024, his final day with the Company.
the Board of Directors of the Company (the “Board”) has appointed Jim Mintern to become the Company’s Chief Executive Officer, effective January 1, 2025.
On September 26. 2024, the Board of Directors of the registrant terminated Mr. Joseph Riccelli as the registrant’s Chief Executive Officer and Chief Financial Officer effective immediately.
Appointed
John L. Thomas
Chief Executor Officer, Chief Financial Officer and corporate counsel
On the same date the Board of Directors appointed John L. Thomas, Esq as the registrant’s Chief Executor Officer, Chief Financial Officer and corporate counsel.
On September 26, 2024, the Century Therapeutics, Inc. (the “Company”) announced the appointment of Morgan Conn, Ph.D. to serve as the Company’s Chief Financial Officer, effective October 14, 2024 (the “Effective Date”).
Mr. Christopher Lotz, Chief Financial Officer of the Company, also tendered his resignation from all positions held with the Company, with such resignation becoming effective immediately.
Mr. Michael Poirier, Chief Executive Officer and Chairman of the board of directors of Qualigen Therapeutics, Inc. (the “Company”), tendered his resignation from all positions held with the Company, with such resignation becoming effective immediately.
On September 25, 2024, the Boards of Directors of the Company and the Bank voted to extend Mr. Quinn’s retirement date to May 25, 2026 and Mr. Quinn accepted this extension.
The same day, Mr. Joe Kiani delivered a notification (the “ Notice ”) to the Board of Directors (the “ Board ”) of the Company stating his decision to resign from his position of Chief Executive Officer of the Company.
On September 24, 2024, the Board appointed Board member Michelle Brennan to serve as the Company’s interim chief executive officer (“ Interim CEO ”) effective immediately.
On September 20, 2024, Ms. Elisabeth A. Eden announced her intention to retire as Senior Vice President and Chief Financial Officer of TXNM Energy, Inc., a New Mexico corporation (“TXNM”), effective as of a date that is mutually agreeable between Ms. Eden and TXNM after a suitable successor is identified, currently anticipated to be no sooner than March 15, 2025 (the “Effective Date”).
Chris Ehrlich, the Vice Chairman of the Board, agreed to serve as Interim Chairman and Chief Executive Officer while the Board searches for a permanent replacement.
On September 22, 2024, the Company’s Chairman and Chief Executive Officer, Brian G. Atwood, informed the Board of his resignation as Chief Executive Officer, effective at a date to be determined, which shall be no later than September 30, 2024.
the Board of Directors (the " Board ") of Thermon Group Holdings, Inc. (the “ Company ”) appointed Jan L. Schott as the Company’s Senior Vice President and Chief Financial Officer, effective October 14, 2024.
the Board appointed Jamie Pirrello, a current member of the Board and a consultant to the Company, as interim Chief Executive Officer of the Company.
Appointed
(interim)
Dr. Cornelius Boersch
interim Chief Financial Officer
Mountain & Co. I Acquisition Corp.
Effective
2024-09-20
Filed
September 24, 2024, 7:59 PM ET
On September 20, 2024, the Board appointed Dr. Cornelius Boersch to serve in the role of interim Chief Financial Officer until a permanent replacement is found.
Appointed
(interim)
Werner Schwock
Interim Chief Financial Officer
HashiCorp, Inc.
Effective
2024-09-24
Filed
September 24, 2024, 7:59 PM ET
the Board has appointed Werner Schwock to serve as the Company’s Interim Chief Financial Officer and function as the principal financial and accounting officer for the Company.
Appointed
Jason A. Zampi
Executive Vice President, Chief Financial Officer and Treasurer
On September 24, 2024, the Board of Directors (the “Board”) of Norfolk Southern Corporation (the “Company”) appointed Jason A. Zampi, the current Acting Chief Financial Officer, as Executive Vice President, Chief Financial Officer and Treasurer (“CFO”).
the Board of Directors (“Board”) of Ammo, Inc (“Company”) named Mr. Paul Kasowski the Company’s new Chief Financial Officer, effective September 20, 2024.
On September 20, 2024, Gregory H. Trepp, the Chief Executive Officer and a member of the Board of Directors (the “Board”) of Hamilton Beach Brands Holding Company (the “Company”), informed the Company of his intention to retire on December 31, 2024, indicating that he has decided to resign as Chief Executive Officer of the Company and as a member of the Board, effective September 30, 2024
On September 19, 2024, the board of directors of TechPrecision Corporation (the “Company”) appointed Richard D. Roomberg to serve as Chief Financial Officer of the Company, effective as of August 20, 2024
as of the Effective Date, Anthony D. Harnett will cease to serve as the Company’s Interim Chief Financial Officer and will continue to serve as the Company’s Senior Vice President and Chief Accounting Officer.
Appointed
Patrick S. Brennan
Executive Vice President and Chief Financial Officer
announced the appointment of Patrick S. Brennan to serve as the Company’s Executive Vice President and Chief Financial Officer (the “Appointment”), with such Appointment to be effective as of October 1, 2024
the Board appointed Noah Aptekar, the Company’s Chief Financial Officer, Chief Operations Officer and director, as the Company’s Chief Executive Officer, effective upon the effectiveness of resignation of Karen Bach.
On September 23, 2024, Owens & Minor, Inc. (the “Company”) announced that Jonathan A. Leon, age 58, has been appointed Executive Vice President, Chief Financial Officer of the Company, effective September 23, 2024.
On September 20, 2024, the Board appointed Catherine Owen Adams, age 54, to serve as the Chief Executive Officer of the Company, including as the “principal executive officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective as of the Transition Date.
On September 17, 2024, the Chief Financial Officer of CERo Therapeutics Holdings, Inc. (the “ Company ”), Charles R. Carter, informed the Board of Directors of the Company (the “ Board ”) that he expects to accept a new position with another publicly-traded company.
the Board of Directors of Q2 Holdings, Inc. (" Q2 ") appointed Jonathan A. Price (age 41), currently Q2’s Executive Vice President, Strategy & Emerging Businesses, as Q2’s Chief Financial Officer, effective on or about November 6, 2024
Mr. Mehok’s departure is not due to any dispute or disagreement with Q2 on any matter relating to Q2’s operations, policies, practices or financial performance.
Departed
Janet Hall
President and Chief Executive Officer
Guardion Health Sciences, Inc.
Effective
2024-10-17
Filed
September 23, 2024, 7:59 PM ET
On September 17, 2024, Guardion Health Sciences, Inc. (the “Company”) announced the termination of Janet (“Jan”) Hall, its President and Chief Executive Officer, effective on October 17, 2024.
On September 20, 2024, the Company appointed Robert Carter to replace Mr. Shah as the Company’s Chief Financial Officer, with effect on October 14, 2024.
On September 19, 2024, Mihir Shah, the Chief Financial Officer, principal financial officer, and principal accounting officer of The Oncology Institute, Inc. (the “Company”), delivered a notice of resignation effective as of October 14, 2024.
Appointed
Ryan Greenier
Executive Vice President and Chief Financial Officer
On September 17, 2024, Horace Mann Educators Corporation (the “Company”) approved the appointment of Ryan Greenier, 42, as Executive Vice President and Chief Financial Officer, effective October 1, 2024, succeeding Bret Conklin.
Departed
Ian Goodkind
Chief Financial Officer
Jamf Holding Corp.
Effective
2024-11-28
Successor
David Rudow
Filed
September 23, 2024, 7:59 PM ET
Mr. Rudow will begin employment with the Company on October 28, 2024 and will succeed Mr. Goodkind as the Company’s new Chief Financial Officer, effective November 28, 2024.
Appointed
David Rudow
Chief Financial Officer
Jamf Holding Corp.
Effective
2024-11-28
Filed
September 23, 2024, 7:59 PM ET
On September 23, 2024, Jamf Holding Corp. (“Jamf” or the “Company”) announced the appointment of David Rudow as Chief Financial Officer of the Company.
the Board appointed Geoff Smith, age 37, who previously served as the Company’s Senior Vice President of Finance, to serve as the Company’s Chief Financial Officer, effective immediately.
On September 17, 2024, the Board of Directors of Rhinebeck Bank, the wholly owned subsidiary of Rhinebeck Bancorp, Inc., provided notice of non-renewal to each of Michael J. Quinn, President and Chief Executive Officer, and Jamie J. Bloom, EVP, Chief Operating Officer & Chief Banking Officer, under each individual’s Amended and Restated Employment Agreement.
Departed
(interim)
David Gaiero
interim principal financial officer and principal accounting officer
In connection with such appointment, David Gaiero, who was serving as the Company’s principal financial officer and principal accounting officer on an interim basis, ceased serving in such capacities as of the Effective Date.
Appointed
Josiah Craver
principal financial officer and principal accounting officer
On September 17, 2024, the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed Josiah Craver as the Company’s principal financial officer and principal accounting officer, effective immediately
Appointed
Kamran Cheema
Chief Executive Officer
ATECH (PARENT) RESOLUTION CORP.
Effective
2024-09-20
Filed
September 20, 2024, 7:59 PM ET
The Board also appointed Mr. Cheema as the Company’s permanent Chief Executive Officer on the same date.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.